Qube Research & Technologies LTD Ideaya Biosciences, Inc. Transaction History

Qube Research & Technologies LTD

$65.7 Billion
Q3 2024

A detailed history of Qube Research & Technologies LTD transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 639,609 shares of IDYA stock, worth $15.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

639,609

Previous 388,252 64.74%

Holding current value

$15.4 Million

Previous $13.6 Million 48.65%

% of portfolio

0.03%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$30.37 - $43.05 $7.63 Million - $10.8 Million	251,357 Added 64.74%	639,609 $20.3 Million
Q2 2024 Aug 14, 2024	BUY	$34.37 - $43.46 $11.3 Million - $14.2 Million	327,737 Added 541.58%	388,252 $13.6 Million
Q1 2024 May 14, 2024	SELL	$34.2 - $47.13 $581,434 - $801,257	-17,001 Reduced 21.93%	60,515 $2.66 Million
Q4 2023 Feb 13, 2024	BUY	$24.59 - $35.83 $1.04 Million - $1.51 Million	42,162 Added 119.26%	77,516 $2.76 Million
Q3 2023 Nov 13, 2023	SELL	$21.07 - $29.77 $809,172 - $1.14 Million	-38,404 Reduced 52.07%	35,354 $953,000
Q2 2023 Aug 14, 2023	BUY	$13.33 - $25.53 $607,381 - $1.16 Million	45,565 Added 161.62%	73,758 $1.73 Million
Q1 2023 May 15, 2023	BUY	$13.49 - $18.72 $380,323 - $527,772	28,193 New	28,193 $387,000
Q2 2022 Aug 15, 2022	SELL	$8.28 - $13.88 $404,378 - $677,871	-48,838 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$11.18 - $24.02 $546,008 - $1.17 Million	48,838 New	48,838 $546,000

Others Institutions Holding IDYA

# of Institutions

210

Shares Held

81M

Call Options Held

69K

Put Options Held

20K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.16B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Ideaya Biosciences, Inc. Transaction History